The results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195) were reported at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014. In 2011, the drug crizotinib earned accelerated approval by the US FDA to target the subset of advanced non-small cell lung cancers caused by rearrangements of the anaplastic lymphoma kinase (ALK) gene, and ...
Read MoreYou have just read an article categorized health
titled New Targetable Form of Disease Highlighted Via Responses With Crizotinib in MET-Amplified Lung Cancer.
Written by:
editor - Sunday, June 1, 2014
There are currently no comments for "New Targetable Form of Disease Highlighted Via Responses With Crizotinib in MET-Amplified Lung Cancer"
Post a Comment